Guggenheim Capital’s Takeda Pharmaceutical TAK Stock Holding History

Guggenheim Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,715	Closed	-$263K	–	2036
2022 Q2	$263K	Sell	18,715 -2,007	-10%	-$28.6K	﹤0.01%	1839
2022 Q1	$297K	Sell	20,722 -85	-0.4%	-$1.25K	﹤0.01%	1889
2021 Q4	$284K	Sell	20,807 -2,224	-10%	-$31.2K	﹤0.01%	1896
2021 Q3	$377K	Buy	23,031 +2,131	+10%	+$35.8K	﹤0.01%	1852
2021 Q2	$352K	Buy	+20,900	New	+$356K	﹤0.01%	1963
2020 Q4	–	Sell	-10,534	Closed	-$188K	–	2114
2020 Q3	$188K	Sell	10,534 -1,229	-10%	-$22.4K	﹤0.01%	1803
2020 Q2	$211K	Sell	11,763 -3,846	-25%	-$69K	﹤0.01%	1728
2020 Q1	$237K	Buy	15,609 +2,127	+16%	+$38.6K	﹤0.01%	1613
2019 Q4	$266K	Buy	13,482 +1,496	+12%	+$28.6K	﹤0.01%	1888
2019 Q3	$206K	Buy	+11,986	New	+$207K	﹤0.01%	1998

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Guggenheim Capital's TAK Position: Q3 2022 in Review

Guggenheim Capital sold out of Takeda Pharmaceutical (TAK) in Q3 2022, closing a stake of 18,715 shares — an estimated $263K sold.

Guggenheim Capital first reported a position in TAK in Q3 2019 and held it in 10 quarters. The position peaked at $377K in Q3 2021. 276 funds tracked by Wall St. Rank hold TAK as of Q3 2022.

Guggenheim Capital reported no remaining Takeda Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Guggenheim Capital sold 18,715 Takeda Pharmaceutical shares in Q3 2022, an estimated $263K.
Guggenheim Capital first reported a position in Takeda Pharmaceutical in Q3 2019 and held it in 10 quarters.
Guggenheim Capital's Takeda Pharmaceutical position peaked at $377K in Q3 2021.
276 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2022.

Based on Guggenheim Capital's 13F filing for Q3 2022, filed 14 Nov 2022.